These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37668187)

  • 41. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
    Bissig D; Manjunath R; Traylor BR; Richman DP; Ng KL
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):e102-e104. PubMed ID: 28416406
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
    Simon A; Domanovits H; Ay C; Sengoelge G; Levy JH; Spiel AO
    J Thromb Haemost; 2017 Jul; 15(7):1317-1321. PubMed ID: 28426914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Idarucizumab (Praxbind)--an antidote for dabigatran.
    Med Lett Drugs Ther; 2015 Nov; 57(1482):157-8. PubMed ID: 26583604
    [No Abstract]   [Full Text] [Related]  

  • 45. Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
    Fang CW; Tsai YT; Chou PC; Chen HM; Lu CM; Tsao CR; Chen CL; Sun MC; Shih YS; Hsieh CY; Chen LA; Chen PL; Yeh JT; Li YH
    J Stroke Cerebrovasc Dis; 2019 Mar; 28(3):815-820. PubMed ID: 30573284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
    Laxamana LC; Co COC; Yu JRT; Mojica CV; Iboleon-Dy MAM; Domingo AMC; Ilano KCS; Macrohon-Valdez MCZ
    Clin Ther; 2020 Sep; 42(9):1840-1845. PubMed ID: 32778345
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dabigatran Reversal with Idarucizumab.
    Yip L; Deng JF
    N Engl J Med; 2017 Oct; 377(17):1690. PubMed ID: 29082732
    [No Abstract]   [Full Text] [Related]  

  • 48. Dabigatran Reversal with Idarucizumab.
    Sorigue M
    N Engl J Med; 2017 Oct; 377(17):1691. PubMed ID: 29082734
    [No Abstract]   [Full Text] [Related]  

  • 49. Reversal of dabigatran by idarucizumab: when and how?
    Vanassche T; Greinacher A; Verhamme P
    Expert Rev Hematol; 2016 Jun; 9(6):519-28. PubMed ID: 27166653
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
    Meyer D; Chu F; Derry K; Hailey L
    J Clin Neurosci; 2019 Jan; 59():355-357. PubMed ID: 30309801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
    Glund S; Reilly P; van Ryn J; Stangier J
    Clin Pharmacokinet; 2017 Feb; 56(2):209-210. PubMed ID: 28028767
    [No Abstract]   [Full Text] [Related]  

  • 52. Appropriate Use of Idarucizumab for Dabigatran Reversal According to the International Society on Thrombosis and Hemostasis and French Working Group on Perioperative Hemostasis: A French Retrospective Study.
    Gendron N; Chocron R; Philippe A; Le Beller C; Lillo-le Louët A; Smadja DM
    J Cardiothorac Vasc Anesth; 2021 Oct; 35(10):3141-3142. PubMed ID: 33715947
    [No Abstract]   [Full Text] [Related]  

  • 53. Reversal of dabigatran using idarucizumab: single center experience in four acute stroke patients.
    Hieber M; Hollasch H; Heck D; Mächtel M; Geisen U; Niesen WD; Brich J; Harloff A
    J Thromb Thrombolysis; 2018 Jul; 46(1):12-15. PubMed ID: 29633066
    [TBL] [Abstract][Full Text] [Related]  

  • 54. idarucizumab (PRAXBIND°). Don't rely too heavily on this dabigatran antidote.
    Prescrire Int; 2016 Nov; 25(176):260-263. PubMed ID: 30715821
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Performance of idarucizumab as antidote of dabigatran in daily clinical practice.
    van der Wall SJ; van Rein N; van den Bemt B; Kruip MJHA; Meijer K; Te Boome LCJ; Simmers TA; Alings AMW; Tieleman R; Klok FA; Huisman MV; Westerweel PE
    Europace; 2019 Mar; 21(3):414-420. PubMed ID: 30339226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Failure of dabigatran following idarucizumab and omeprazole administration.
    Mahawish KM; Leung A
    Intern Med J; 2021 Jan; 51(1):134-135. PubMed ID: 33572021
    [No Abstract]   [Full Text] [Related]  

  • 57. Idarucizumab for Dabigatran Reversal in Emergency Type-A Aortic Dissection.
    Henderson RS; Deshpande S; Williams B; Taylor BS; Tanaka KA
    J Cardiothorac Vasc Anesth; 2017 Dec; 31(6):e80-e81. PubMed ID: 27498256
    [No Abstract]   [Full Text] [Related]  

  • 58. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idarucizumab Reversal of Dabigatran in Patients with Acute Ischemic Stroke and Intracranial Hemorrhage: Comparison with Non-idarucizumab-Treated Patients.
    Frol S; Sernec LP; Hudnik LK; Šabovič M; Oblak JP
    CNS Drugs; 2021 Feb; 35(2):233-242. PubMed ID: 33548038
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: Two cases with hemorrhagic transformation.
    Tsai YT; Hsiao YJ; Tsai LK; Yen PS; Lin FY; Lu CH; Fang CW
    J Neurol Sci; 2018 May; 388():155-157. PubMed ID: 29627012
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.